Catalyst
Slingshot members are tracking this event:
Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CERC |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 21, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cerc-301, Major Depressive Disorder
